Cargando…
Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2
BACKGROUND: Hexokinase (HK) is the rate-limiting enzyme in the first reaction of glycolysis. And Hexokinase 2 (HK2) is most closely related to malignant tumor which expresses at higher level compared with normal cells. HK2 plays a pivotal role in tumor initiation and maintenance, which provides a ne...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399312/ https://www.ncbi.nlm.nih.gov/pubmed/28427443 http://dx.doi.org/10.1186/s13046-017-0530-4 |
_version_ | 1783230615837999104 |
---|---|
author | Li, Wei Zheng, Mengzhu Wu, Shuangping Gao, Suyu Yang, Mei Li, Zhimei Min, Qiuxia Sun, Weiguang Chen, Lixia Xiang, Guangya Li, Hua |
author_facet | Li, Wei Zheng, Mengzhu Wu, Shuangping Gao, Suyu Yang, Mei Li, Zhimei Min, Qiuxia Sun, Weiguang Chen, Lixia Xiang, Guangya Li, Hua |
author_sort | Li, Wei |
collection | PubMed |
description | BACKGROUND: Hexokinase (HK) is the rate-limiting enzyme in the first reaction of glycolysis. And Hexokinase 2 (HK2) is most closely related to malignant tumor which expresses at higher level compared with normal cells. HK2 plays a pivotal role in tumor initiation and maintenance, which provides a new target for cancer therapy. METHODS: Structure-based virtual ligand screening was used in hit identification from ZINC Drug Database. Microscale thermophoresis assay was performed to evaluate the binding affinity. Enzyme inhibition, cytotoxicity, apoptosis, intracellular ATP level, mitochondrial membrane potential (MMP), glucose uptake and lactate production experiments were undertaken in SW480 cells to identify Benz as a HK2 inhibitor. Western blot was used to test protein expression. SW480 cells xenograft mouse models were used for in vivo study. Nano-particles of Benz were prepared to improve the antitumor efficacy and tumor targeting of Benz. HPLC was used to measure the concentration of free Benz in tumor tissues. RESULTS: Benserazide (Benz), was identified as a selective HK2 inhibitor, could specifically bind to HK2 and significantly inhibit HK2 enzymatic activity in vitro. In addition, Benz reduced glucose uptake, lactate production and intracellular ATP level, and could cause cell apoptosis and an increased loss of MMP as well. In vivo study indicated that intraperitoneal (ip) injection of Benz at 300 and 600 mg/Kg suppressed cancer growth in tumor-bearing mice and no toxicity shown. To further improve the antitumor efficacy and tumor targeting of Benz, nano-particles of Benz was prepared. Liposomal Benz at 100 and 200 mg/Kg performed potent inhibitory effects on tumor-bearing mice, showing reduced dose and better efficacy. CONCLUSIONS: Our study provides a new direction for the development of Benz and its analogues as novel antitumor agents for cancer therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-017-0530-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5399312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53993122017-04-24 Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 Li, Wei Zheng, Mengzhu Wu, Shuangping Gao, Suyu Yang, Mei Li, Zhimei Min, Qiuxia Sun, Weiguang Chen, Lixia Xiang, Guangya Li, Hua J Exp Clin Cancer Res Research BACKGROUND: Hexokinase (HK) is the rate-limiting enzyme in the first reaction of glycolysis. And Hexokinase 2 (HK2) is most closely related to malignant tumor which expresses at higher level compared with normal cells. HK2 plays a pivotal role in tumor initiation and maintenance, which provides a new target for cancer therapy. METHODS: Structure-based virtual ligand screening was used in hit identification from ZINC Drug Database. Microscale thermophoresis assay was performed to evaluate the binding affinity. Enzyme inhibition, cytotoxicity, apoptosis, intracellular ATP level, mitochondrial membrane potential (MMP), glucose uptake and lactate production experiments were undertaken in SW480 cells to identify Benz as a HK2 inhibitor. Western blot was used to test protein expression. SW480 cells xenograft mouse models were used for in vivo study. Nano-particles of Benz were prepared to improve the antitumor efficacy and tumor targeting of Benz. HPLC was used to measure the concentration of free Benz in tumor tissues. RESULTS: Benserazide (Benz), was identified as a selective HK2 inhibitor, could specifically bind to HK2 and significantly inhibit HK2 enzymatic activity in vitro. In addition, Benz reduced glucose uptake, lactate production and intracellular ATP level, and could cause cell apoptosis and an increased loss of MMP as well. In vivo study indicated that intraperitoneal (ip) injection of Benz at 300 and 600 mg/Kg suppressed cancer growth in tumor-bearing mice and no toxicity shown. To further improve the antitumor efficacy and tumor targeting of Benz, nano-particles of Benz was prepared. Liposomal Benz at 100 and 200 mg/Kg performed potent inhibitory effects on tumor-bearing mice, showing reduced dose and better efficacy. CONCLUSIONS: Our study provides a new direction for the development of Benz and its analogues as novel antitumor agents for cancer therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-017-0530-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-20 /pmc/articles/PMC5399312/ /pubmed/28427443 http://dx.doi.org/10.1186/s13046-017-0530-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Li, Wei Zheng, Mengzhu Wu, Shuangping Gao, Suyu Yang, Mei Li, Zhimei Min, Qiuxia Sun, Weiguang Chen, Lixia Xiang, Guangya Li, Hua Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 |
title | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 |
title_full | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 |
title_fullStr | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 |
title_full_unstemmed | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 |
title_short | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 |
title_sort | benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399312/ https://www.ncbi.nlm.nih.gov/pubmed/28427443 http://dx.doi.org/10.1186/s13046-017-0530-4 |
work_keys_str_mv | AT liwei benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT zhengmengzhu benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT wushuangping benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT gaosuyu benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT yangmei benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT lizhimei benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT minqiuxia benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT sunweiguang benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT chenlixia benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT xiangguangya benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 AT lihua benserazideadopadecarboxylaseinhibitorsuppressestumorgrowthbytargetinghexokinase2 |